Pantoprazole-induced thrombocytopenia.

Area of Science:

• Pharmacology
• Hematology
• Internal Medicine

Background:

• Proton-pump inhibitors (PPIs) are widely used for acid-related gastrointestinal disorders.
• Drug-induced thrombocytopenia is a known adverse effect of various medications, but PPIs are not typically strongly suspected.
• Understanding rare adverse drug reactions is crucial for patient safety.

Observation:

• Two hospitalized patients developed thrombocytopenia (low platelet count) after initiating pantoprazole 40 mg.
• Thrombocytopenia emerged shortly after pantoprazole treatment began in both cases.
• Platelet counts improved rapidly after pantoprazole was discontinued, though full recovery was not immediate in one patient.

Findings:

• A probable causal relationship between pantoprazole and thrombocytopenia was established using the Naranjo probability scale in both cases.
• The mechanism underlying pantoprazole-induced thrombocytopenia remains poorly understood.
• It is currently unknown if this adverse effect is specific to pantoprazole or a class effect among proton-pump inhibitors.

Implications:

• Although rare, pantoprazole-associated thrombocytopenia is a potentially severe adverse drug event.
• This finding underscores the importance of cautious prescribing of pantoprazole and other proton-pump inhibitors.
• Clinicians should remain vigilant for hematological adverse effects during PPI therapy.